23 September 2023 false No description of principal activity Taxfiler 2024.6 15158267 business:PrivateLimitedCompanyLtd 2023-09-23 2025-01-31 15158267 2023-09-22 15158267 2023-09-23 2025-01-31 15158267 business:AuditExemptWithAccountantsReport 2023-09-23 2025-01-31 15158267 business:FilletedAccounts 2023-09-23 2025-01-31 15158267 2025-01-31 15158267 business:Director1 2023-09-23 2025-01-31 15158267 business:RegisteredOffice 2023-09-23 2025-01-31 15158267 core:WithinOneYear 2025-01-31 15158267 core:ShareCapital core:PreviouslyStatedAmount 2025-01-31 15158267 core:CapitalContributionReserve core:PreviouslyStatedAmount 2025-01-31 15158267 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2025-01-31 15158267 core:PreviouslyStatedAmount 2025-01-31 15158267 business:SmallEntities 2023-09-23 2025-01-31 15158267 countries:EnglandWales 2023-09-23 2025-01-31 iso4217:GBP xbrli:pure
Company Registration No. 15158267 (England and Wales)
Brava Labs Ltd Unaudited accounts for the period from 23 September 2023 to 31 January 2025
Brava Labs Ltd Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Brava Labs Ltd Company Information for the period from 23 September 2023 to 31 January 2025
Director
Graham Cooke
Company Number
15158267 (England and Wales)
Registered Office
86-90 Paul Street London EC2A 4NE England
Accountants
Lilley & Co (UK) Limited Suite 8 57 High Street Ibstock Leicestershire LE67 6LH
- 3 -
Brava Labs Ltd Statement of financial position as at 31 January 2025
2025
Notes
£
Current assets
Debtors
4
123,439
Cash at bank and in hand
125,375
248,814
Creditors: amounts falling due within one year
5
(216,532)
Net current assets
32,282
Net assets
32,282
Capital and reserves
Called up share capital
1
Capital contribution reserve
627,951
Profit and loss account
(595,670)
Shareholders' funds
32,282
For the period ending 31 January 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 16 March 2026 and were signed on its behalf by
Graham Cooke Director Company Registration No. 15158267
- 4 -
Brava Labs Ltd Notes to the Accounts for the period from 23 September 2023 to 31 January 2025
1
Statutory information
Brava Labs Ltd is a private company, limited by shares, registered in England and Wales, registration number 15158267. The registered office is 86-90 Paul Street, London, EC2A 4NE, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Research and development
Expenditure on research and development is written off in the year in which it is incurred.
Foreign exchange
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
Financial instruments - SAFE investments
The Company issues Simple Agreements for Future Equity (SAFEs) to raise capital. These instruments do not create a contractual obligation to pay cash or deliver other financial assets, as they convert into shares upon a qualifying future equity financing event. Therefore, the proceeds from the issuance of SAFEs are classified as equity (noted under 'Capital Contribution Reserve') and are not remeasured. Material transaction costs associated with the issuance are deducted from equity
Deferred taxation
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the company's accounts. Deferred tax is provided in full on timing differences which result in an obligation to pay more (or less) tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.
4
Debtors
2025
£
Amounts falling due within one year
VAT
1,224
Amounts due from group undertakings etc.
119,148
Other debtors
3,067
123,439
- 5 -
Brava Labs Ltd Notes to the Accounts for the period from 23 September 2023 to 31 January 2025
5
Creditors: amounts falling due within one year
2025
£
Taxes and social security
7,926
Loans from directors
161,348
Accruals
47,258
216,532
6
Average number of employees
During the period the average number of employees was 0.
- 6 -